GSK falls as FDA advisors vote against approving blood cancer drug

4 hours ago 1

A group of independent advisors to the U.S. Food and Drug Administration (FDA) on Thursday voted against the approval of a combination drug regimen involving GSK’s (NYSE:GSK) blood cancer medicine Blenrep.
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 5-3 against the

Recommended For You